Leveraging functional genomics to reveal novel targets for cancer treatment

Applicant types

SME, Large company, Research org, University

Purpose

Research and innovation

R&D relevance

3 of 3

Poland eligible

Yes

Country limit

—

Region

Any

Consortium

Unclear

Readiness level (TRL)

—

Topics

• Functional genomics
• Tumour heterogeneity
• Cancer therapeutic targets
• Multimodal clinical data

Machine-classified from the call text; check eligibility at the source. 23 Oct 2026

Typed facts extracted from the source documents by Scindu's grant-data review. Each value keeps its own conditions. Unknown means unstated, not zero or unlimited.

Applicant restriction

Participation and funding eligibility are distinct. Eligible participation remains subject to the Horizon Europe Regulation and topic conditions. Beneficiaries and affiliated entities register in the Participant Register before submission to obtain a PIC; legal validation and proof of legal status/origin are completed before grant signature, but a validated PIC is not a submission prerequisite. Associated partners may participate subject to the topic without signing the GA or charging costs/claiming contributions. General funding categories include EU Member States (including outermost regions), Overseas Countries and Territories, Associated Countries, and the listed low-/middle-income countries. Other entities receive funding only where the topic provides or the granting authority finds participation essential. Check applicable country status/list and call-specific exceptions. The general consortium default, unless specific call/topic conditions provide otherwise, is three mutually independent beneficiary legal entities established in three different countries: at least one in a Member State and two others each in different Member States or Associated Countries. Affiliated entities do not count toward this minimum. The JRC, international European research organisations and entities created under EU law are treated as established in a Member State different from those of other participants. Training/mobility and CoFund applications may be submitted by one or more entities if one is established in a Member State or Associated Country. Apply the three-beneficiary default only subject to any express own-topic exception; none is inferred from action-class wording alone.

Applicant restriction

For this assigned topic the source-bound action class is RIA. Apply the general China rule by that class: the IA bar applies to IA; the default RIA bar and its listed exceptions apply only to RIA and only for the matching Work Programme destination. Do not transpose either rule to CSA, PCP or CoFund. The all-action MIIT-supervised Chinese public-university exclusion remains applicable. General Annex B: China-established legal entities are excluded from every IA and, unless stated otherwise, every RIA. The listed RIA destination exceptions are Cluster 2: Innovative Research on Democracy and Governance; Innovative research on European cultural heritage and cultural and creative industries; Innovative research on social and economic transformations. Cluster 5: Climate sciences and responses for the transformation towards climate neutrality. Cluster 6: Biodiversity and ecosystem services; Fair, healthy and environment-friendly food systems; Clean environment and zero pollution; Land, ocean and water for climate action; Resilient, inclusive, healthy and green rural/coastal/urban areas; and Innovative governance, environmental observations and digital solutions in support of the Green Deal. Missions: EU Missions’ Joint Calls; Adaptation to Climate Change; Restore our Ocean and Waters; and A Soil Deal for Europe. Widening: Widening participation and spreading excellence; Reforming and enhancing the European research and innovation system. New European Bauhaus Facility: Connecting the green transformation, social inclusion and local democracy; Innovative funding and new business models for neighbourhood transformation. Horizontal Activities: Transformative change towards a nature-positive economy and society. The listed destination exceptions are RIA exceptions only: they do not lift the China-established-entity exclusion for an IA. For an RIA, a China-established entity is excluded unless this call’s exact destination is one of the listed RIA exceptions; only when the destination matches may the entity participate in any capacity. A justified case-by-case exception may also be granted under the source rule. For IA and RIA restrictions that apply, exclusion covers participation in any capacity. MIIT-supervised Chinese public universities remain ineligible for any action. Evaluate this packet’s own action and exact destination before applying an exception. Entities subject to EU restrictive measures are not eligible in any capacity, including beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of FSTP. Entities established in Russia, Belarus or non-government-controlled territories of Ukraine are likewise ineligible in any capacity even when not subject to EU restrictive measures; a justified case-by-case exception may be granted. Russian-established persons/entities/bodies whose direct or indirect proprietary rights exceed 50% in an entity established outside Russia make that entity ineligible in any capacity. These rules are distinct from call-specific ownership/control restrictions, which apply only when identified in the relevant Work Programme/topic conditions. Communications-network supplier restrictions and critical-technology/control restrictions apply only when identified in the relevant work-programme/topic conditions; they are not automatic for every call. Russian-established persons/entities/bodies that directly or indirectly hold proprietary rights exceeding 50% in an entity established outside Russia make that entity ineligible in any capacity. Hungarian public-interest trusts established under Act IX of 2021 and entities they maintain may apply, but while Council measures remain in force cannot take any funded role (including beneficiaries, affiliated entities, subcontractors, or recipients of FSTP); in multi-beneficiary calls the applicant is invited to remove/replace them from funded roles or change them to associated-partner status, with tasks and budget redistributed accordingly. Affected entities can participate without EU funding as associated partners if call conditions allow. These conditions do not establish eligibility for any particular participant.

Applicant restriction

Under adopted Horizon Europe General Annex B, This RIA’s destination is not among the Annex B exceptions; China-established legal entities are ineligible in any capacity. MIIT-supervised public Chinese universities are also barred. In all actions, a public Chinese university established in China and administered by or under MIIT supervision is ineligible. This is a participant-eligibility rule; it does not determine other applicants' eligibility.

Applicant restriction

Financial capacity is normally checked for the coordinator when requested grant is at least EUR 500,000, with exceptions for public bodies/international organisations and individual requested amounts no more than EUR 60,000. Checks may extend to other applicants, affiliated entities or guarantors; weak capacity can lead to safeguards or rejection. Operational capacity is assessed through the implementation award criterion; the form requests participant/researcher identity, up to five relevant achievements and up to five relevant prior projects/activities per participant, plus significant infrastructure/equipment. Public bodies, Member State organisations and international organisations are exempt from that operational-capacity check. Administrative sanctions and listed exclusion grounds bar participation, including insolvency, tax/social-security breaches, grave professional misconduct, fraud/corruption/criminal and financial-integrity offences, serious prior grant/contract failures, irregularities, circumvention and unremediable procurement-preparation conflicts; misrepresentation/non-supply and irremediable equality-of-treatment distortion are also refusal grounds. These legal/capacity checks are separate from award scores and do not certify a specific participant.

Applicant restrictionAdopted General Annex B; only if the own-topic action activates this restriction

Where the specific action is expressly identified as subject to restrictions for protection of European communication networks, entities assessed as high-risk suppliers of mobile network communication equipment and entities they own or control are ineligible as beneficiaries, affiliated entities or associated partners. Assessment includes third-country interference/ownership/governance/business/legal context, supply-chain cybersecurity practices and relevant security assessments. Exceptions may be requested from the granting authority, which assesses them case by case using the 5G toolbox criteria, security risks and availability of alternatives in the action. This conditional general clause does not activate the restriction for an unflagged topic or extend the listed participation roles.

Own-topic activation and other separately stated country/control restrictions retain their distinct scope.

Applicant restrictionHORIZON-MISS-2027-02-CANCER-01 only; the own-topic eligibility block expressly makes it subject to the Annex B restriction for European communication networks.

This CANCER-01 RIA topic expressly adopts the General Annex B restrictions for the protection of European communication networks. Entities assessed as high-risk suppliers of mobile-network communication equipment, and entities they own or control, are ineligible to participate as beneficiaries, affiliated entities or associated partners. The assessment considers the likelihood of interference from a non-associated third country, including ownership/governance, business conduct and third-country characteristics, cybersecurity practices across the supply chain, and risks identified by relevant authorities. An exception may be requested from the granting authority; it is assessed case by case against the 5G cybersecurity toolbox criteria, security risks and availability of alternatives in the action context.

The restriction is specifically for entities assessed as high-risk suppliers of mobile-network communication equipment and entities they own/control, in the listed participation roles. Do not expand it to every telecommunications/network entity. An exception is requestable and case-by-case, not automatic. This is the expressly adopted Annex B B8–9 network rule; it is distinct from Annex B China/MIIT rules handled in common A–C review.

Application restriction

Submit electronically using the forms in the Portal system (topic-page templates are informational), following the form instructions. Applications must include all parts and mandatory annexes/supporting documents and be readable, accessible and printable. Full applications include an exploitation/dissemination/communication plan unless the topic provides otherwise; no such plan is required for stage 1 of a two-stage process. Where relevant, include a commercial exploitation strategy; where exploitation is primarily in non-associated third countries, explain why it is in the EU interest. General Annex A defaults: full application 40 pages, except CSA 25 and Programme Co-fund 65; for lump-sum topics RIA/IA 45 and CSA 28; stage 1 is 10 pages. The specific topic and actual Portal form/template override defaults. Blind first-stage anonymisation applies only when the topic specifies blind evaluation. If an application exceeds the applicable page limits, the submission system gives an automatic warning and invitation to resubmit a conforming version. After the call deadline, excess pages are automatically made invisible and are not considered by evaluators. Actual topic conditions and Portal submission templates govern the applicable limits and sections. This procedure does not promise a post-deadline correction window or say the whole application is automatically rejected.

Application restriction

Projects must focus exclusively on civil applications and comply with EU policy interests/priorities. Applicants complete an ethics self-assessment; projects raising ethics issues undergo ethics review and may receive ethics deliverables/authorisation requirements. Security appraisal/classified-information conditions apply only when classified or sensitive information is involved. A GEP is an eligibility requirement at grant signature and throughout the grant only for MS/AC public bodies, research organisations and higher-education establishments applying as beneficiaries or affiliated entities. It must be published, top-management-signed/adopted, resourced, monitor sex/gender-disaggregated data with reporting at least every two years, and include staff/decision-maker awareness or training; equivalent strategic documents can satisfy the process requirements. GEP eligibility does not apply to other legal-entity categories. Separately, beneficiaries must take measures to promote equal opportunities and, where applicable, follow the GEP; they should aim, to the extent possible, for gender balance at all personnel levels, including supervisory/managerial levels. This is an implementation aim, not a numerical staffing quota. A self-declaration is requested in the Participant Register. Source-listed GEP content areas are recommendations, not extra mandatory eligibility items.

Application restrictionHORIZON-MISS-2027-02-CANCER-01; adopted AnnexE, subject to stage-specific templates

Use the electronic Portal system and complete all parts, mandatory annexes and supporting documents. PartA contains organisation/administrative data, summary budget and call questions; PartB is the technical PDF description. Upload supporting documents in system-permitted formats. Design the proposal around the award criteria. Coordinator confirms mandate, correctness/completeness and all participants’ eligibility/capacity/exclusion compliance; each participant reconfirms by declaration of honour before signature. Noncompliance can cause rejection and later legal-entity/financial/bank validation documents may be requested. Actual stage-specific Portal templates and own-topic conditions govern.

Application restrictionEvaluation review; actual/deemed access anchors, not submission or project deadlines

Coordinator may request review of procedural flaws, following evaluation-result-letter procedures/deadlines; merits are not reviewed. Each request concerns one specific proposal, within30days after opening/access of results, maximum7000characters. Notifications unopened for10days after sending are deemed accessed. A review committee may recommend re-evaluation, primarily by experts not involved previously, or confirmation of the initial evaluation.

Application restrictionDefault full-application ranking within one budget envelope; own special arrangements retained

Adopted General Annex F default for proposals with the same score within one budget envelope, excluding stage 1 of two-stage submissions and subject to any specific call/topic special arrangement: first prioritise call aspects not covered by more highly ranked proposals. Those identified proposals are then prioritised by Excellence and then Impact; for Innovation Actions the order is Impact then Excellence. If necessary, use gender balance among named leading researchers; then geographical diversity by MS/AC not otherwise receiving funds from higher-ranked projects (number first, then budget if equal). If still indistinguishable, the panel may use documented call/Horizon-objective factors, for example project-portfolio synergies or relevant feasible SME involvement. This is a priority procedure, not a funding guarantee, staffing quota or first-stage tie rule.

Application restriction

09 Feb 2027 planned opening date.

Application restriction

21 Sep 2027; call dates are at 17:00 Brussels local time.

Consortium required

Yes

Unless topic conditions provide otherwise, three independent beneficiary legal entities from different countries are required: one EU Member State and two others from different Member States or Associated Countries; affiliated entities do not count.

Eligible project scopeHORIZON-MISS-2027-02-CANCER-01, own-topic expected outcomes, physical pp.88–89.

Proposals should aim to deliver results directed and tailored towards and contributing to all three expected outcomes: (1) researchers and health professionals gain a deeper understanding of the functional effects of tumour heterogeneity during cancer initiation and progression, supporting identification of more precise and novel therapeutic targets; (2) researchers, health professionals and innovators benefit from improved knowledge and tools for discovery and development of next-generation genomically informed cancer treatments; and (3) researchers, innovators and professionals across disciplines and sectors contribute to the UNCAN.eu research data platform through interoperable data and sustainable access to new digital tools and models for multimodal clinical-data analysis and management.

The source says proposals should aim to contribute to ALL listed outcomes; this describes intended results and is not rewritten as a separate hard eligibility criterion.

Eligible project scopeHORIZON-MISS-2027-02-CANCER-01, own-topic scope and implementation conditions, physical pp.89–90.

Applicants should address all three topic activities: identify and validate new therapeutic targets using experimental models and technologies that access functional effects of tumour temporal heterogeneity on initiation, progression and relapse; investigate mechanisms linking dynamic tumour multi-omics, its microenvironment and patient-specific factors during initiation/progression, including adaptive resistance and clinical data where appropriate; and apply state-of-the-art approaches, tools and models to integrate and analyse FAIR multimodal longitudinal patient data. Proposals may use exploratory mechanistic, clinical proof-of-concept, observational or translational studies as appropriate. Functional-genomics and structural-biology advances (including sequencing, single-cell studies, spatial mapping/transcriptomics, epigenetic profiling, liquid biopsies and functional precision oncology) are encouraged, as are causal inference, computational modelling and AI for complex data. Interdisciplinary collaboration is envisaged; proposals should include an appropriate mix of stakeholders such as medical doctors, health-IT experts, researchers, AI experts, solution providers, academia/research institutes, EU research infrastructures and SMEs. Digital assets should be made available through UNCAN.eu and datasets described with metadata in the EHDS EU dataset catalogue. ESFRI life-science infrastructures, including biobanking options, should be appropriately reflected in the workplan. Proposals should take advantage, to the extent possible, of data and experience from the European 1M+ Genomes and European Cancer Imaging initiatives; successful proposals are expected to establish appropriate collaboration with UNCAN-CONNECT. Successful proposals will be asked to join the Cancer Mission “Understanding” cluster and should budget for networking, meetings and joint activities; detailed activity plans are not required at proposal stage. Applicants envisaging clinical studies should provide details in the dedicated annex using the submission-system template. The own-topic scope says paediatric and adolescent cancers, cancers with limited treatment options, refractory cancers, rare cancers, and cancer types with low five-year survival rates are of particular interest; this is a non-exclusive priority description, not an exclusion of other cancers. Its footnote gives genetic background, immune status, age, sex and comorbidities as examples of patient-specific factors for the multi-omics investigation, not quotas or separate mandatory participant categories.

The three activities are introduced as “Applicants should address all”; preserve “should” rather than hardening to an absolute legal eligibility requirement. Encouraged techniques, envisaged collaboration and the appropriate stakeholder mix remain non-exhaustive source guidance. Reuse of the named European initiatives is only to the extent possible; biobanking/ESFRI reflection is a workplan recommendation. Clinical-annex details are conditional on envisaging a clinical study and should use the submission-system template; do not rewrite this as a universal mandatory annex or “must observe” rule. The “of particular interest” cancer categories are non-exclusive scope priorities, not eligibility exclusions. “Low five-year survival rates” is the source’s clinical outcome descriptor, not a project-duration requirement or a numeric survival-rate threshold. Genetic background, immune status, age, sex and comorbidities are illustrative patient-specific examples in footnote 130, not quotas or mandatory stand-alone participant categories.

Eligible project scope

Cancer R&I topic focused on functional genomics and novel therapeutic targets; the expected EU contribution is indicative, not a cap.

Expected number of grants (planning estimate)Expected grants for the exact assigned action HORIZON-MISS-2027-02-CANCER-01, as recorded in the frozen SEDIA budget overview.

4 planned grant awards

This is a provider-published planning count for the call action, not a guaranteed award count, applicant count, or staffing/headcount.

Other condition

Research and Innovation Actions.

Other condition

Each Excellence, Impact and Implementation threshold is 4; cumulative threshold is 12.

Other conditionHORIZON-MISS-2027-02-CANCER-01; RIA full-application award aspects; not first-stage full-rubric scoring

For RIA full applications evaluated under adopted AnnexD, assess the action-specific qualitative aspects. Excellence: clarity/pertinence of objectives and ambition beyond the state of the art; sound methodology, including underlying concepts/models/assumptions, interdisciplinary approaches, appropriate research-content gender dimension, and quality of open-science practices including research-output sharing/management and citizen/civil-society/end-user engagement where appropriate. Impact: credible pathways to expected work-programme outcomes/impacts; suitable, high-quality measures to maximise them through the dissemination/exploitation plan, including communication. Implementation: effective, high-quality work plan, risk assessment, appropriate work-package effort and overall resources; each participant’s capacity/role and the consortium’s necessary expertise. Aspects are considered to the extent relevant to the work-programme description; scores are for criteria, not separate scores for each aspect. Own-topic exceptions and the separately recorded stage-specific score rules retain priority.

Other conditionGeneral Annex F default limitations; individual part budget denominator and call-specific procedures

Invitation to grant preparation is no formal funding commitment; legal/capacity/exclusion checks remain. Call/topic budgets are indicative; unless otherwise stated final figures may change up to20% relative to the total budget in each individual work-programme part, not an automatic project or topic increase. Seals of Excellence/STEP seals, joint-call selection, blind first-stage evaluation and partial randomisation depend on explicit own-call conditions; none follows automatically from two-stage status. The tie method in points1–4 is reapplied to remaining equally ranked proposals.

Other conditionDefault indicative evaluation/grant-preparation timetable; own-topic timeline prevails

Absent different own-call conditions, evaluation outcome is around5months after submission deadline and grant signature around8months. Two-stage default: around3months from stage1deadline for its outcome; around5months from stage2deadline for its outcome, and around8months from stage2deadline for grant signature. Indicative planning estimates, not fixed promises or project/employment duration.

Other conditionHORIZON-MISS-2027-02-CANCER-01; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement

Grant preparation with the EU project officer sets deliverables, reporting/payments, grant amount, rate, eligible costs and duration in the agreement. Budget is EUR and award may be below request. Start normally follows signature; retroactive start and month-based duration extensions need exceptional justified granting-authority agreement. Portal manages milestones/deliverables reflected in agreementAnnex1. For ACTUAL-COST grants only eligible incurred costs are reimbursed at the agreed rate; surplus/profit is deducted and noncompliance may reduce grant. This conditional actual-cost description does not reclassify an expressly lump-sum/unit topic: its rate is already applied in amount-setting and does not appear as a separately added reimbursement percentage. Own-topic grant form/rate, PCPprocurement conditions and partnership amendment restrictions remain.

Other conditionHORIZON-MISS-2027-02-CANCER-01; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement

Agreement covers proper implementation, conflicts, confidentiality/security/classified information, ethics/integrity/values/gender, data protection, IPR/background/results/access/use, communication/dissemination/open science/visibility and applicable special action rules. Additional adopted duties: if granting authority requests during a public emergency, grant nonexclusive result licences on fair/reasonable terms for its stated limited period to entities committed to rapid broad exploitation; provision applies up to4years after action end. Unless own-call states otherwise, notify authority for up to4years after end when results could reasonably contribute to European/international standards. Authority may object to ownership transfer/exclusive licensing for up to4years after end ONLY where specific call provides. Give data/result access needed to validate publication conclusions while safeguarding legitimate interests/constraints unless access already given. On authority request in public emergency, immediately deposit research outputs and provide CC BY,CC0 or equivalent open access; where legitimate interests preclude this, provide the stated nonexclusive fair/reasonable licences instead, with that exception limited to4years after end. Breach/other legal violations may trigger agreementChapter5 measures; no unread AGA provisions or executed applicant agreement are asserted.

Other conditionHORIZON-MISS-2027-02-CANCER-01; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement

After signature, normal initial float is160% of average EU funding per reporting period: maximum grant amount divided by number of reporting periods. Exceptionally less or no pre-financing is possible. With ONLY ONE reporting period it will be less, since100% would already equal the whole grant; no fixed single-period percentage is specified. Programme co-fund actions may receive additional pre-financing. At pre-financing,5–8% of maximum grant is deducted into the mutual-insurance mechanism, not added as a benefit or treated as funding intensity. EU debts may offset/reduce payments. Interim payments link to periodic reports; final report determines final grant and overpayment is recovered. Financial-statement certificate thresholds depend on grant size/beneficiary type and the agreement, not an invented universal amount. Recovery liability is individual: beneficiary’s own and affiliated-entity debts. These normal/general arrangements do not guarantee a new payment on an existing partnership amendment or displace express own-topic/agreement provisions.

Other condition

If at least one application targeting children and adolescents aged 0–19 at first diagnosis attains all thresholds, the call will award at least one grant to a highest-ranked qualifying application in that age-targeting portfolio, even where this is not the next application in strict overall ranking order. No award is guaranteed if no application in that portfolio attains all thresholds.

Indicative budget

€32,323,812

Topic budget as stated in the portal's budget table. Lump-sum and per-project limits are in the call conditions.

Eligible costHORIZON-MISS-2027-02-CANCER-01; adopted General Annex G baseline subject to express own-topic grant provisions and actual agreement

Agreement fixes cost forms/categories: eligible actual personnel/subcontracting/purchases and FSTP only if call permits; units may cover personnel, SMEowners/naturalpersons without salary, usual-practice average personnel and internally invoiced goods/services, and expressly permitted specific units. The25%indirect-cost base excludes subcontracting,FSTP and units/lump sums already containing indirect costs. Different cost forms can coexist; global/action-category lump sums require call provision. Several EU Synergy grants may declare costs only where cumulative funding does not exceed100% of eligible costs/contributions declared. These are budget/eligibility methods, not personal salary or automatic FSTP/unit-cost permission; separately recorded own-topic costs/forms and rates retain priority.

Funding intensity, maximum

100 percent of eligible costs

General Horizon Europe action-type rate; the grant agreement and any applicable topic-specific conditions govern the final award.

Indirect cost flat rateIndirect-cost calculation for the assigned Horizon Europe action HORIZON-MISS-2027-02-CANCER-01.

25 percent of eligible direct costs

General Annex G applies a 25% flat rate to eligible direct costs after excluding eligible direct subcontracting, financial support to third parties, and unit costs or lump sums that already include indirect costs. This percentage describes the indirect-cost calculation, not funding intensity.

Expected project funding, up to

€8,000,000

Indicative contribution range, not a cap; different amounts may be requested.

Expected project funding, from

€7,000,000

Indicative contribution range, not a cap; different amounts may be requested.

Topic allocation

€32,320,000

Topic allocation, not per-project or beneficiary cap; subject to appropriations.

• Horizon Europe General Annexes2026–2027

  ec.europa.eu

• Horizon Europe Work Programme 2026-2027, Part 12 Missions

  ec.europa.eu

Opens

10 Feb 2027

Deadline model

Single-stage

Programme

Horizon Europe · 2021 - 2027

Call

HORIZON-MISS-2027-02 · Supporting the implementation of the Cancer Mission

Types of action

HORIZON Research and Innovation Actions

Keywords

• Cancer onset
• Cancer progression
• Functional Genomics
• Therapeutic targets

Source

ec.europa.eu

Checked

23 Oct 2026

Portal updated

7 Oct 2026

Review status

Partial review

Reviewed

24 Oct 2026